- Supernus Pharmaceuticals (SUPN, Financial) is set to release its first quarter 2025 financial results on May 6, 2025, after market close.
- The company will host a conference call and webcast at 4:30 p.m. ET, featuring President and CEO Jack Khattar, along with Senior VP and CFO Tim Dec.
- The webcast can be accessed via the company's Investor Relations website and will remain available for 60 days post-event.
Supernus Pharmaceuticals, Inc. (SUPN), a specialist in the development and commercialization of products targeting central nervous system (CNS) disorders, has announced its schedule to release the financial and business results for the first quarter of 2025. The announcement is slated for Tuesday, May 6, 2025, subsequent to the market's closure.
An earnings call will be hosted on the same day at 4:30 p.m. ET. The call will feature insights from Jack Khattar, President and CEO, along with Tim Dec, Senior Vice President and CFO. Following the presentation of the financial and business outcomes, a Q&A session will be held for participants.
Investors and interested parties can access the live webcast through the Events & Presentations section on the Supernus Investor Relations website. For those wanting a more personalized experience, pre-registration is available, providing participants with a unique conference code. The replay of the webcast will be accessible on the company's website for 60 days following the live event.
Supernus Pharmaceuticals continues to advance its research and development portfolio, focusing on innovative treatments for diseases such as ADHD, Parkinson's disease, epilepsy, migraine, and other CNS disorders. For further information, visit the company's official website at www.supernus.com.
